glp 1 for pediatrics Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Pediatric Obesity | Current Treatment Options in Pediatric Obesity Management in the

The analysis included eight randomized controlled trials with 2,372 participants (all with BMI 27 kg/m) and found that weight regain was proportional to the amount initially lost.48 On average, participants who had taken liraglutide regained 2.2 kg, while those who had taken semaglutide or tirzepatide regained 9.69 kg after stopping the medication.48 Similarly, a 2025 review in Biomolecules showed that patients treated with GLP-1 or dual GLP-1/GIP agonists experience substantial weight loss (ranging from about 6% to over 20%) but also significant weight regain upon drug discontinuation

Bowel Leakage and Incontinence

GLP-1 drugs are widely used in this population, yet robust clinical guidance is still evolving

This work was partially supported by National Natural Science Foundation of China 81872915 (M.-W.W.), 82073904 (M.-W.W.), 81922071 (Y.Z.), 81773792 (D.Y.), 81973373 (D.Y.) and 21704064 (Q.Z.)

Voc deve considerar avaliao com endocrinologista se: Tem obesidade ou sobrepeso com comorbidades J tentou emagrecer sem sucesso com dieta e atividade fsica Tem diabetes tipo 2 de difcil controle Est em risco de doena cardiovascular ou esteatose heptica Tem histrico familiar de obesidade grave Quer evitar cirurgia baritrica ou buscar alternativas modernas Concluso: um novo captulo no tratamento da obesidade e do diabetes Estamos vivendo um marco histrico na medicina